Products for Research Use Only

Tulmimetostat

CAT: 0804-HY-145602-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145602-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies[1][2][3][4].
CAS Number
2567686-02-4
Product Name Alternative
CPI-0209
UNSPSC
12352005
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tulmimetostat.html
Concentration
10mM
Purity
99.79
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C2C(O[C@@](O2)([C@]3([H])CC[C@](N4CC(C4)OC)([H])CC3)C)=C(C=C1C(NCC5=C(C=C(NC5=O)C)SC)=O)Cl
Molecular Formula
C28H36ClN3O5S
Molecular Weight
562.12
References & Citations
[1]WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.|[2]Drescher C, et al. EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) : preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC) 2023.|[3]Morschhauser F, et al. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Rev. 2022 Nov;56:100988.|[4]Qiu J, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12 (15) :1415-1430.|[5]Rentian Wu, et al. Abstract 2126: Therapeutic potential of CPI-0209. Cancer Res 1 July 2021; 81 (13_Supplement) : 2126.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
EZH1; EZH2